A Randomized Trial of Electrographic Flow-Guided Redo Ablation for Nonparoxysmal Atrial Fibrillation (FLOW-AF).
Vivek Y ReddyAnke LangbeinJan PetruTamas Szili-TorokMoritoshi FunasakoLeon DinshawSip WijchersAndreas RilligStefan G SpitzerRohit BhagwandienAndreas MetznerMelissa H KongPetr NeuzilPublished in: JACC. Clinical electrophysiology (2024)
In nonparoxysmal AF patients undergoing redo ablation, EGF mapping identified AF sources in 60% of patients, and could be successfully ablated in 95%. Compared with PVI alone, PVI + source ablation improved AF-free survival by 51% on an absolute basis. (FLOW-AF: A Study to Evaluate the Ablacon Electrographic FLOW EGF Technology [A Randomized Controlled Study to Evaluate the Reliability of the Ablacon Electrographic FLOW (EGF) Algorithm Technology (Ablamap Software) to Identify AF Sources and Guide Ablation Therapy in Patients With Persistent Atrial Fibrillation]; NCT04473963).
Keyphrases
- atrial fibrillation
- catheter ablation
- left atrial
- oral anticoagulants
- left atrial appendage
- direct oral anticoagulants
- heart failure
- free survival
- patients undergoing
- growth factor
- percutaneous coronary intervention
- end stage renal disease
- drinking water
- radiofrequency ablation
- newly diagnosed
- ejection fraction
- stem cells
- chronic kidney disease
- deep learning
- mesenchymal stem cells
- acute coronary syndrome
- patient reported
- smoking cessation